Skip to Content
Merck
  • Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.

Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.

Cell death & disease (2016-05-07)
T Taniguchi, Y Iizumi, M Watanabe, M Masuda, M Morita, Y Aono, S Toriyama, M Oishi, W Goi, T Sakai
ABSTRACT

Resveratrol has various attractive bioactivities, such as prevention of cancer, neurodegenerative disorders, and obesity-related diseases. Therefore, identifying its direct binding proteins is expected to discover druggable targets. Sirtuin 1 and phosphodiesterases have so far been found as the direct molecular targets of resveratrol. We herein identified 11 novel resveratrol-binding proteins, including the DEAD (Asp-Glu-Ala-Asp) box helicase 5 (DDX5, also known as p68), using resveratrol-immobilized beads. Treatment with resveratrol induced degradation of DDX5 in prostate cancer cells. Depletion of DDX5 caused apoptosis by inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling. Moreover, knockdown of DDX5 attenuated the inhibitory activities of resveratrol against mTORC1 signaling and cancer cell growth. These data show that resveratrol directly targets DDX5 and induces cancer cell death by inhibiting the mTORC1 pathway.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-p68 Antibody, clone204, clone 204, Upstate®, from mouse
Pricing and availability is not currently available.